Starton Therapeutics

Transforming therapies with proprietary dermal delivery technology, so people with cancer live better, longer

Start a new standard

Starton Therapeutics is transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, longer.

Targeted continuous delivery

We transform FDA-approved medicines and leverage our dermal delivery systems to establish new profiles. Our platform technology enables lower but longer drug exposure and the potential for improved efficacy.

Careers

Building a team dedicated to delivering breakthrough, transformative products for patients with blood cancers.We offer comprehensive and competitive health, financial, paid time off and many other benefits designed to promote the health and well-being of our employees and their families.

News and Events

March 26, 2025

Starton Therapeutics to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2025

PARAMUS, N.J., March 26, 2025 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today that the Company…

December 3, 2024

Starton Therapeutics to Present at Biotech Showcase 2025

PARAMUS, N.J., December 3, 2024 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today that Chairman and…